Tips for searching:
• You have to select a product and type at least 2 words to activate the search
• Use only words that are specific to the information you are looking for
• Avoid typing questions or sentences
Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow card in the Google play or Apple app store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Omvoh ® ▼ (mirikizumab)
This information is intended for UK registered healthcare professionals only in response to your search for information. For current information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk
Omvoh® (mirikizumab): Preparation and administration of intravenous infusion
Prepare the infusion using aseptic technique. Mirikizumab should be diluted in either 0.9% sodium chloride or 5% glucose solution for injection and administered for at least 30 minutes.
Must the infusion solution be removed before adding mirikizumab to the bag?
There is no requirement to withdraw a volume of 0.9% Sodium Chloride Injection or 5% Dextrose Injection solution from the infusion bag that is equal to the 15 mL (300 mg) Omvoh solution to be added to the infusion solution in the bag. 1
During clinical trials investigational sites were not required to consistently use the same volume each time an infusion was administered. Omvoh just had to be infused in a 50 mL to 250 mL infusion solution as directed to be compliant with the protocol. 1
Health care providers must therefore follow the guidance of the prescribing information / Summary of Product Characteristics (EU) when preparing the infusion solution for administration. Do not use infusion bags in which the labeled nominal volume of the bag is less than 50 mL or greater than 250 mL as stability has not been demonstrated under those dilution conditions. 1
References
1Data on file, Eli Lilly and Company and/or one of its subsidiaries.
2Omvoh [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Date of Last Review: 16 May 2023